(Q34203216)

31 July 2017

1 reference

title

Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

31 July 2017

1 reference

1 reference

1 reference

5

Naveed Sattar

1 reference

31 July 2017

Lyndal Harborne

1

1 reference

31 July 2017

Richard Fleming

series ordinal

2

1 reference

31 July 2017

Helen Lyall

series ordinal

3

1 reference

31 July 2017

Jane Norman

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

31 July 2017

1 reference

31 July 2017

361

1 reference

31 July 2017

9372

1 reference

31 July 2017

1894-1901

1 reference

Polycystic ovary syndrome

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Current concepts in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Insulin resistance in nonobese patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Polycystic ovary syndrome: a risk for coronary artery disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

The blooming of the French lilac

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Insulin-sensitising agents in polycystic-ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin in management of pregnant insulin-independent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Oral hypoglycaemic agents in 118 diabetic pregnancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Obesity and reproductive disorders: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

The effect of metformin on hirsutism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2913493-9

7 January 2021

10.1016/S0140-6736(03)13493-9

Identifiers

DOI

1 reference

31 July 2017

1 reference